Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics Incorporated (DGX) Q3 2025 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q3 2025 Earnings Call October 21, 2025 8:30 AM EDT Company Participants Shawn Bevec - Vice President of Investor Relations James Davis - Chairman, CEO & President Sam Samad - Executive VP & CFO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Michael Cherny - Leerink Partners LLC, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Kevin Caliendo - UBS Investment Bank, Research Division Jack Meehan - Nephron Research LLC Luke Sergott - Barclays Bank PLC, Research Division David Westenberg - Piper Sandler & Co., Research Division Erin Wilson Wright - Morgan Stanley, Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division Michael Ryskin - BofA Securities, Research Division Pito Chickering - Deutsche Bank AG, Research Division Tycho Peterson - Jefferies LLC, Research Division Eric Coldwell - Robert W.
Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DGX posts a strong Q3 with revenues and EPS beating estimates, higher margins and an upbeat full-year outlook.
Quest Diagnostics (DGX) Surpasses Q3 Earnings and Revenue Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.6 per share, beating the Zacks Consensus Estimate of $2.51 per share. This compares to earnings of $2.3 per share a year ago.
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings
DGX is poised for solid Q3 2025 results, backed by strong DIS growth, strategic M&A and robust test demand across key health segments.
Quest Diagnostics: Investing In Healthcare's Future Today
Quest Diagnostics (DGX) remains a buy, which is also what the consensus today said too. Quest can benefit from continued demand for specific diagnostic testing across a broad range of clinical areas. It has proven itself as a cashflow and dividend grower, achieving strong margins among peers and similar competitor Labcorp, and making progress on FDA approvals.
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing
DGX teams up with Epic on Project Nova to streamline lab testing, boost efficiency, and enhance patient and provider experiences.
DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute
Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.
DGX Stock Gains Following a New Joint Venture With Corewell Health
Quest Diagnostics shares rise after forming a joint venture with Corewell Health to expand advanced lab services across Michigan.
Why Is Quest Diagnostics (DGX) Up 8.2% Since Last Earnings Report?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
Should Quest Diagnostics Stock Be in Your Portfolio Right Now?
DGX drives growth with advanced diagnostics, acquisitions and cost savings, but rising debt and macro risks weigh on its outlook.
